196 related articles for article (PubMed ID: 18006704)
1. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma.
Chatterjee M; Rancso C; Stühmer T; Eckstein N; Andrulis M; Gerecke C; Lorentz H; Royer HD; Bargou RC
Blood; 2008 Apr; 111(7):3714-22. PubMed ID: 18006704
[TBL] [Abstract][Full Text] [Related]
2. Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer.
Gunasekaran VP; Nishi K; Sivakumar D; Sivaraman T; Mathan G
Eur J Pharm Sci; 2018 Apr; 116():2-14. PubMed ID: 28916481
[TBL] [Abstract][Full Text] [Related]
3. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells.
Basaki Y; Hosoi F; Oda Y; Fotovati A; Maruyama Y; Oie S; Ono M; Izumi H; Kohno K; Sakai K; Shimoyama T; Nishio K; Kuwano M
Oncogene; 2007 Apr; 26(19):2736-46. PubMed ID: 17072343
[TBL] [Abstract][Full Text] [Related]
4. Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle.
Yu YN; Yip GW; Tan PH; Thike AA; Matsumoto K; Tsujimoto M; Bay BH
Int J Oncol; 2010 Aug; 37(2):483-92. PubMed ID: 20596676
[TBL] [Abstract][Full Text] [Related]
5. The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival.
Bommert KS; Effenberger M; Leich E; Küspert M; Murphy D; Langer C; Moll R; Janz S; Mottok A; Weissbach S; Rosenwald A; Bargou R; Bommert K
Leukemia; 2013 Feb; 27(2):441-50. PubMed ID: 22772059
[TBL] [Abstract][Full Text] [Related]
6. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.
Dahl E; En-Nia A; Wiesmann F; Krings R; Djudjaj S; Breuer E; Fuchs T; Wild PJ; Hartmann A; Dunn SE; Mertens PR
BMC Cancer; 2009 Nov; 9():410. PubMed ID: 19930682
[TBL] [Abstract][Full Text] [Related]
7. ABCG2 expression, function, and promoter methylation in human multiple myeloma.
Turner JG; Gump JL; Zhang C; Cook JM; Marchion D; Hazlehurst L; Munster P; Schell MJ; Dalton WS; Sullivan DM
Blood; 2006 Dec; 108(12):3881-9. PubMed ID: 16917002
[TBL] [Abstract][Full Text] [Related]
8. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells.
Dhillon J; Astanehe A; Lee C; Fotovati A; Hu K; Dunn SE
Oncogene; 2010 Nov; 29(47):6294-300. PubMed ID: 20802512
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD21 antigen on myeloma cells and its involvement in their adhesion to bone marrow stromal cells.
Huang N; Kawano MM; Mahmoud MS; Mihara K; Tsujimoto T; Niwa O; Kuramoto A
Blood; 1995 Jun; 85(12):3704-12. PubMed ID: 7780154
[TBL] [Abstract][Full Text] [Related]
10. Effect of YB-1 on the regulation of micro RNA expression in drug-sensitive and drug-resistant gastric carcinoma cells.
Belian E; Kurucz R; Treue D; Lage H
Anticancer Res; 2010 Feb; 30(2):629-33. PubMed ID: 20332481
[TBL] [Abstract][Full Text] [Related]
11. Transcription factors Xbp-1, Blimp-1, and BSAP are involved in the regulation of plasmacytic differentiation induced by 2-methoxyestradiol in myeloma cell lines.
Jiang H; Gao W; Sze DM; Xiong H; Hou J
Int J Hematol; 2007 Dec; 86(5):429-37. PubMed ID: 18192112
[TBL] [Abstract][Full Text] [Related]
12. Regulation of mRNA expression in drug-sensitive and drug-resistant gastric carcinoma cells is independent of YB-1 expression.
Kurucz R; Belian E; Treue D; Lage H
Anticancer Res; 2010 Feb; 30(2):693-8. PubMed ID: 20332492
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.
Wang J; Hendrix A; Hernot S; Lemaire M; De Bruyne E; Van Valckenborgh E; Lahoutte T; De Wever O; Vanderkerken K; Menu E
Blood; 2014 Jul; 124(4):555-66. PubMed ID: 24928860
[TBL] [Abstract][Full Text] [Related]
14. shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines.
Xu P; Jiang YF; Wang JH
Int J Clin Exp Pathol; 2015; 8(3):2300-10. PubMed ID: 26045737
[TBL] [Abstract][Full Text] [Related]
15. Role of interleukin 16 in multiple myeloma.
Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
[TBL] [Abstract][Full Text] [Related]
16. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer.
Shiota M; Zoubeidi A; Kumano M; Beraldi E; Naito S; Nelson CC; Sorensen PH; Gleave ME
Mol Cancer Res; 2011 Dec; 9(12):1755-66. PubMed ID: 21987172
[TBL] [Abstract][Full Text] [Related]
17. Intracellular localization and content of YB-1 protein in multidrug resistant tumor cells.
Vaiman AV; Stromskaya TP; Rybalkina EY; Sorokin AV; Guryanov SG; Zabotina TN; Mechetner EB; Ovchinnikov LP; Stavrovskaya AA
Biochemistry (Mosc); 2006 Feb; 71(2):146-54. PubMed ID: 16489918
[TBL] [Abstract][Full Text] [Related]
18. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.
Saupe M; Rauschenberger L; Preuß M; Oswald S; Fussek S; Zimmermann U; Walther R; Knabbe C; Burchardt M; Stope MB
World J Urol; 2015 Oct; 33(10):1481-6. PubMed ID: 25544376
[TBL] [Abstract][Full Text] [Related]
20. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
